Follow-on Biologic's Day Will Come - Post 2015, Teva Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.
You may also be interested in...
Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015
Despite a string of uncharacteristic setbacks, Teva remains confident in its long-term strategy and five-year financial goals it outlined a year ago.
Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015
Despite a string of uncharacteristic setbacks, Teva remains confident in its long-term strategy and five-year financial goals it outlined a year ago.
Teva's Laquinimod Meets Primary Endpoint In First Phase III Study
Favorable safety profile may differentiate Teva's laquinimod from competing oral multiple sclerosis therapies.